Castle Biosciences (CSTL)
(Delayed Data from NSDQ)
$20.34 USD
+0.83 (4.25%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $20.38 +0.04 (0.20%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Earnings News For CSTL
-
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
-
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
-
Castle Biosciences Reports Third Quarter 2023 Results
-
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
-
Castle Biosciences Reports Second Quarter 2023 Results
-
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
-
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
-
Castle Biosciences Reports First Quarter 2023 Results
-
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
-
Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results
-
Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates
-
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
-
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
-
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
-
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
-
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q4 Earnings Expected to Decline
-
Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Lags Revenue Estimates
-
Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for
-
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
-
Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for
-
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
-
Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for
-
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
-
Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates